REG - Haleon PLC - Director Declaration

RNS Number : 8295P Haleon PLC 21 January 2026 Haleon plc: Director Declaration21 January 2026: Haleon plc (LSE/NYSE: HLN) announces that Dawn Allen, Chief Financial Officer, has been appointed Chair of the Audit & Risk Committee of ITV plc with effect from 5 March 2026.Dawn has served as a Non‑Executive Director of ITV plc and a member of its Audit & Risk Committee since 2 October 2023.This notification is made in accordance with the requirements of Listing Rule 6.4.9R(2).Amanda MellorCompany SecretaryAbout HaleonHaleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.For more information, please visit www.haleon.com. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RDNBBMITMTJTBFF